Print Page    E-mail Page    RSS    E-mail Alerts 

2016 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
11/23/16
Bellerophon Therapeutics, Inc. Announces $12 Million Public Offering
WARREN, N.J., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the pricing of a public offering with expected total gross proceeds of approximately $12 million. The offering is expected to close on or about November 29, 2016, subject to satisfaction of customary closing conditions. The offering was priced at $0.70 per Class A Unit (consisting of one share of our common stock and a warrant to purchase on... 
11/08/16
Bellerophon Reports Third Quarter 2016 Financial Results and Provides Business Update
WARREN, N.J., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported financial results for the third quarter ended September 30, 2016 and provided a business update. “Overall, I am pleased to report good progress in our ongoing Phase 3 clinical trial to treat Pulmonary Arterial Hypertension (PAH), under an FDA-granted Special Protocol Assessment,” stated Jonathan Peacock, Chairman and Chief Executive Officer o... 
09/20/16
Bellerophon Therapeutics Announces Planned Management Transition by Year-End 2016
WARREN, N.J., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the planned transition of Fabian Tenenbaum, current Chief Financial Officer and Chief Business Officer, to Chief Executive Officer of the company, succeeding Jonathan Peacock, who will retain his position as Chairman of the Board and remain actively involved. The transition will be completed by year-end. Commenting on the management transit... 
09/06/16
Bellerophon to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
WARREN, N.J., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will present at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held at Lotte New York Palace Hotel in New York City. Bellerophon management will provide a Company update during the live presentation and will be available to participate in one-on... 
08/09/16
Bellerophon Reports Second Quarter 2016 Financial Results and Provides Business Update
WARREN, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported financial results for the second quarter ended June 30, 2016 and provided a business update. “This quarter, we made important progress on our development plans across our clinical pipeline,” stated Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics. “As planned, in June we enrolled our first patient in our Phase ... 
07/25/16
Bellerophon Receives Approval to Commence Phase 2 Trial in PH-COPD
-- Trial expected to commence in third quarter; Results to be reported by year end 2016 -- -- Previous data supporting testing long-term benefits of pulsed inhaled nitric oxide (iNO) reported in peer-reviewed International Journal of COPD -- WARREN, N.J., July 25, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced it has received health authority approval in Belgium to commence a Phase 2 trial for INOpulse, its pat... 
06/16/16
Bellerophon Therapeutics Announces Enrollment of the First Patient in the INOvation-1 Phase 3 Clinical Trial for Pulmonary Arterial Hypertension (PAH)
WARREN, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, announced today that the first subject has been enrolled in the Phase 3 INOvation-1 clinical trial.  The first patient was enrolled by Jeremy Feldman, MD, Principal Investigator at Arizona Pulmonary Associates, Ltd. INOvation-1 is a clinical trial evaluating the efficacy and safety of the INOpulse® delivery system for the treatment of patients with Pulmonar... 
05/10/16
Bellerophon Reports First Quarter 2016 Financial Results and Provides Business Update
WARREN, N.J., May 10, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported financial results for the first quarter ended March 31, 2016 and provided a business update. “During the first quarter, we advanced our clinical and operational plans,” stated Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics. “With receipt of FDA and EMA approval for our global Phase 3 clinical program for INO... 
03/21/16
Bellerophon Reports 2015 Financial Results and Provides Business Update
– Company Receives Final FDA Confirmation to Initiate Phase 3 Studies Using Next Generation INOpulse Device –  – Management to Host a Conference Call Today at 8:30 a.m. ET – WARREN, N.J., March 21, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported financial results for the year ended December 31, 2015 and provided a business update. Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutic... 
03/14/16
Bellerophon Therapeutics to Hold Full Year 2015 Financial Results Conference Call on Monday March 21, 2016
WARREN, N.J., March 14, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will release its full year 2015 financial results before the open of the U.S. financial markets on March 21, 2016. Management will host a conference call at 8:30 am ET the same day. Access information:   Date: Monday, March 21, 2016 Time:  8:30 am Eastern time Dial-in n... 
03/04/16
Bellerophon Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference
WARREN, N.J., March 04, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will present in the Cowen and Company 36th Annual Health Care Conference. Jonathan Peacock, Bellerophon’s Chairman and Chief Executive Officer, will provide a company update at 2:00 pm ET on Monday, March 7, 2016.   About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovati... 
03/02/16
Bellerophon Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WARREN, N.J., March 02, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported that in connection with the appointment of Fabian Tenenbaum as Chief Financial Officer and Chief Business Officer, the Company entered into an employment arrangement with Mr. Tenenbaum which provided for the grant of an inducement equity award outside the Company's 2015 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).  ... 
02/23/16
Bellerophon Therapeutics Appoints Fabian Tenenbaum as Chief Financial Officer and Chief Business Officer
WARREN, N.J., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the appointment of Fabian Tenenbaum as Chief Financial Officer and Chief Business Officer. “We are delighted to welcome Fabian to Bellerophon as Chief Financial Officer and Chief Business Officer,” stated Jonathan Peacock, Bellerophon’s Chairman and Chief Executive Officer. “Fabian brings nearly 15 years of executive-level experience in fin... 
02/16/16
Bellerophon Therapeutics Appoints Mary Ann Cloyd as an Independent Board Member
WARREN, N.J., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the appointment of Mary Ann Cloyd as an independent director.  Ms. Cloyd will also serve as a member of the Audit Committee. Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics, noted, "We are delighted to welcome Mary Ann to the Company.  Mary Ann brings tremendous expertise in finance, senior management and cor... 
02/09/16
Bellerophon Therapeutics Announces Positive Data From the Final Analysis of the Phase 2 Long-Term Extension Study of INOpulse for Treatment of Pulmonary Arterial Hypertension
Long-Term Extension Data Reinforces Earlier Phase 2 Data and Indicates Sustainability of Benefits for PAH Patients WARREN, N.J., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced positive data from the final analysis of the Company’s Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company’s Phase 2 trial).  The Phase 2 long-term ext... 
02/03/16
Bellerophon to Participate in LEERINK Partners 5th Annual Global Healthcare Conference
WARREN, N.J., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will participate in LEERINK Partners 5th Annual Global Healthcare Conference. Jonathan Peacock, Bellerophon’s Chairman and Chief Executive Officer, will take questions during a fireside chat at 10:40 am ET on Wednesday, February 10, 2016. A live webcast may be accessed under the investor tab at www.bellerophon.com. An archive of the... 
01/21/16
Bellerophon Therapeutics Announces Notice of Intention to Grant a European Patent Supporting Its INOpulse Program
WARREN, N.J., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that the European Patent Office has issued a Notice of Intention to Grant a European Patent that provides protection for the company’s INOpulse program.  The patent, entitled “System of Administering a Pharmaceutical Gas to a Patient,” covers the ability to provide a known amount of pharmaceutical gas to a patient regardless of the patient insp... 
01/19/16
Bellerophon Therapeutics Receives EC Certification for New INOpulse® Drug-Device Delivery System
WARREN, N.J., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has received EC Certification for its proprietary new, INOpulse® drug-device delivery system. This EC Certification grants CE marking on the INOpulse product, which confirms INOpulse compliance with the essential requirements of the relevant European health, safety and environment protection legislation of the European Union.  This cert...